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Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS)
with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.  
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lym-
phadenectomy were randomized into equal groups to receive adjuvant chemotherapy of
eight cycles of DS (S-1 70 mg/m2/day on days 1-14 plus docetaxel 35 mg/m2 on days 1 and
8) every 3 weeks or SP (S-1 70 mg/m2/day on days 1-14 plus cisplatin 60 mg/m2 on day 1)
every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients
to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was
approved based on the CLASSIC study, it was decided to close the study early. With a median
follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not signif-
icantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4
adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had
more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome
(4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in
DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned
treatment. 
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with 
curatively resected stage III gastric cancer.
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Introduction
Gastric cancer is the second leading cause of the cancer
death worldwide, and is particularly prevalent in Eastern
Asia, Eastern Europe, and South America [1]. The overall 
5-year relative survival rate was 37.8% in the Surveillance,
Epidemiology, and End Results data [2], and 55.7% in the
Korea National Cancer Incidence Database [3] for locally 
advanced gastric cancer. Complete surgical resection remains
the only chance of a cure in gastric cancer patients, and gas-
trectomy with D2 lymphadenectomy is a standard surgical
treatment for locally advanced gastric cancer. Since approx-
imately 40% to 80% of gastric cancer patients still suffer 
recurrence and ultimately die from the disease [4], there has
always been an urgent need for effective adjuvant che-
motherapy or radiotherapy. The recent adjuvant trials in gas-
tric cancer have shown improved survival in patients treated
with adjuvant chemotherapy compared to those who under-
went surgery alone [5,6] especially in Asia. Based on individ-
ual patient data from 17 randomized clinical trials, meta-
analysis from the GASTRIC (Global Advanced/Adjuvant
Stomach Tumor Research International Collaboration) group
showed that postoperative adjuvant chemotherapy based on
a fluorouracil regimen was associated with longer survival
in gastric cancer compared with surgery alone [7]. In 2007, a
large-scale study by the Adjuvant Chemotherapy Trial of 
S-1 for Gastric Cancer (ACTS-GC) group reported the first
positive phase III result addressing superiority of adjuvant
chemotherapy with an oral fluoropyrimidine, S-1 monother-
apy versus surgery [5]. However, subgroup analysis revealed
that S-1 only provided a survival benefit among patients with
an early disease stage (II or IIIA) who had undergone D2 gas-
trectomy [8]. Therefore, a more efficient chemotherapy regi-
men, for example one based on a drug doublet, is needed to
improve the outcome of patients with locally advanced—
especially stage III—gastric cancer after curative resection.
With only limited adjuvant S-1 monotherapy benefit in stage
III gastric cancer patients even after 5-year follow up period
of the ACTS-GC trial [8], and no general consensus about the
best adjuvant treatment option, we designed a phase III trial
to establish the effectiveness of an S-1 containing doublet reg-
imen for advanced American Joint Committee on Cancer
(AJCC) seventh stage III patients after curative gastrectomy.
Capecitabine plus oxaliplatin seems to be effective for 
advanced stage II and III gastric cancer patients, but the high
incidence of hand-foot syndrome and peripheral neuropathy
are toxic for many patients [6]. And the CLASSIC trial result
was not available when we planned this phase III trial. 
Because S-1 is tolerable and widely accepted as an effective
therapeutic agent for resected gastric cancer in an adjuvant
setting, adding other cytotoxic agent seemed reasonable.
In order to identify an efficient doublet antineoplastic reg-
imen that could improve treatment outcome, among late
stage advanced gastric cancer patients after D2 gastrectomy,
the Post Operation chemotherapy with S-1 and Taxotere in
curatively resected gastric cancer of stage III (POST) study
was designed. This study compared the effect of two adju-
vant S-1 based doublet regimens, S-1 plus docetaxel (DS)
with S-1 plus cisplatin (SP), on the disease-free survival (DFS)
of D2 resected stage III gastric cancer patients. There have
been several previous randomized control trials of DS or SP
as palliative treatments in metastatic gastric cancer [9-11], but
there has been no phase III study to directly compare these
two doublet regimens, or to assess their use in adjuvant ther-
apy for D2 resected stage III advanced gastric cancer.
Materials and Methods
1. Study design and treatment 
The POST trial was an open-label, phase III, randomized
controlled study, performed in eight centers in South Korea.
The primary aim of the study was to compare the DFS fol-
lowing S-1 doublets between DS and SP. Gastrectomy with
D2 lymphadenectomy has been performed as a standard
procedure by all of the surgeons who participated in this trial
and the pathology reports were standardized based on D2
dissection in each institute. The patients were randomly 
assigned to 6 months of treatment with eight cycles of either
DS (intravenous docetaxel [35 mg/m2 on days 1 and 8 of each
cycle] plus oral S-1 [35 mg/m2 twice daily on days 1 to 14 of
each cycle]) every 3 weeks, or SP (intravenous cisplatin [60
mg/m2 on day 1] plus S-1 [same dosage utilized in DS])
every 3 weeks. Oral S-1 was ministered after meal within one
hour. Pre-hydration before intravenous cisplatin following
the institutional protocol was mandatory to prevent nephro-
toxicity. The randomization was stratified by institution and
disease stage (IIIA vs. IIIB vs. IIIC). Each stratum was ran-
domized using the randomly permuted block method. 
2. Patients
Inclusion criteria for patients were that they should have
histopathologically confirmed AJCC seventh stage III gastric
adenocarcinoma; undergone R0 resection (with no residual
microscopic tumor cells including margin) with D2 lymph
node dissection; age of 20 years or older; adequate renal func-
tion (creatinine clearance > 50 mL/min), hepatic function
(total bilirubin  1.5 times the upper limit of normal [ULN],
aspartate or alanine aminotransferase  2.5 times the ULN,
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alkaline phosphatase  2.5 times the ULN), and hematologi-
cal function (absolute neutrophil count  1.5109/L or
platelet count  100109/L); and had an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1. 
Exclusion criteria were as follows: a tumor other than ade-
nocarcinoma; pregnancy or breast feeding; evidence of
metastasis including peritoneal or distant metastasis; any
previous treatment of cytotoxic chemotherapy, radiotherapy,
or immunotherapy for gastric cancer; previous major surgery
within 4 weeks before the start of the trial, or a failure to 
recover from the surgery; previous history of other malig-
nancies within 5 years except for cured skin basal cell carci-
noma or cured in situ cervix cancer; gastrointestinal obstru-
ction or malabsorption syndrome that can negatively affect
S-1 absorptions; R1 or R2 resection; other severe medical con-
ditions; known dihydropyrimidine dehydrogenase defici-
ency; sensitivity to platinum agents or docetaxel; and ina-
dequate organ function. All the patients had been random-
ized into either treatment group within 8 weeks after sur-
gery.
3. Study end points and assessments 
Three-year DFS rate was chosen as the primary endpoint
because a recent meta-analysis showed that DFS is an accept-
able surrogate end point for overall survival (OS) in trials of
cytotoxic agents for gastric cancer in the adjuvant setting [12].
DFS was defined as the time from randomization to the time
of recurrence of gastric cancer or death from any cause, and
was to be analyzed by intent-to-treat. Secondary end points
included OS, defined as the time from randomization to the
time of death from any cause, and safety profiles (adverse
events). Tumors were assessed radiographically using com-
puted tomography at screening (baseline), every 3 months
after randomization during years 1 and 2, every 6 months
during year 3, and then yearly.
Toxicity was closely monitored during each treatment
cycle, and adverse events were graded according to the 
National Cancer Institute’s Common Terminology Criteria
for Adverse Events ver. 4.0. The dose of each chemothera-
peutic agent could be reduced if any of the following toxici-
ties occurred in the preceding cycle: grade 4 leukopenia,
neutropenia or thrombocytopenia, febrile neutropenia grade
3 or higher, non-hematologic toxicity grade 3 or higher 
except for hand foot syndrome, cardiac toxicity, and elevated
bilirubin of grade 2 or higher. The study drugs were discon-
tinued if recovery did not occur within 3 weeks from the
planned day 1.
4. Statistical methods
The intent-to-treat (ITT) patient population, the population
for all primary analyses, included all randomly assigned 
patients who had received at least one cycle of their allocated
treatment. Three-year DFS rate, the primary end point, was
predicted to be 40.0% and 55.0% in SP group and DS group,
respectively (hazard ratio [HR], 0.65), based on two docetaxel
and cisplatin combined studies [9,13]. Kaplan-Meier estimates
and Cox regression analyses of DFS and OS were calculated.
The two groups were compared using the stratified log-rank
test. With a predicted median follow-up duration of 3 years,
173 events were necessary to ensure 80% power for a two-
sided test at a significance level of 0.05. A sample size of 145
patients in each group was planned, allowing for a 10%
dropout rate. The safety analysis included all the ITT patients.
SPSS ver. 20 (IBM Corp., Armonk, NY) and the statistical soft-
ware package R ver. 13.0 were used for statistical analyses. A
p-value of less than 0.05 was considered statistically signifi-
cant.
5. Accrual and time of analysis
In January 2012, the phase III capecitabine and oxaliplatin
adjuvant study in stomach cancer (CLASSIC) study showed
a survival benefit of adjuvant capecitabine and oxaliplatin
chemotherapy compared to surgery alone, among stage 
II-III gastric cancer patients who had undergone curative D2
gastrectomy [6]. Based on this trial, in March 2013, the 
Korean Food and Drug Administration approved the use of
capecitabine and oxaliplatin for adjuvant chemotherapy after
curative gastrectomy. Since patients could be reimbursed by
National Insurance of Korea for the use of capecitabine and
oxaliplatin as an adjuvant therapy, the accrual rate of the
POST trial was reduced. The trial committee decided to close
the study early with the last patient enrolled in July 2013, and
the data cut-off date was April 30, 2017.
6. Ethical statement
The protocol was approved by the institutional review and
ethics board of each participating center. The study was con-
ducted in accordance with the Declaration of Helsinki and
the Good Clinical Practice Guidelines defined by the Inter-
national Conference on Harmonization. All patients pro-
vided written, informed consent before enrollment. The trial
is registered at ClinicalTrials.gov (NCT01283217).
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Table 1.  Baseline patients’ characteristics 
Characteristic DS (n=75) SP (n=78)
Sex
Male 46 (61.3) 56 (71.8)
Female 29 (38.7) 22 (28.2)
Age, median (range, yr) 54 (33-74) 58 (25-72)
ECOG performance
0 45 (60.0) 53 (67.9)
1 30 (40.0) 25 (32.1)
Cell type (WHO classification)
Tubular adenocarcinoma well differentiated 0 ( 2 (0.3)
Tubular adenocarcinoma moderately differentiated 20 (26.7) 26 (33.3)
Tubular adenocarcinoma poorly differentiated 34 (45.2) 35 (44.9)
Signet ring cell 17 (22.7) 13 (16.7)
Hepatoid adenocarcinoma 1 (2.4) 0 (
Mucinous adenocarcinoma 2 (2.7) 1 (2.4)
Undifferentiated adenocarcinoma 1 (2.4) 1 (2.4)
Lauren classification
Intestinal type 11 (14.7) 16 (20.5)
Diffuse type 29 (38.7) 18 (23.1)
Mixed 2 (2.7) 8 (10.3)
Unknown 33 (44.0) 36 (45.2)
No. of retrieved lymph nodes, median (interquartile range) 43 (34-55) 40 (29-53)
Tumor stage
T2 2 (2.7) 3 (3.8)
T3 15 (20.0) 24 (30.8)
T4 58 (77.3) 51 (65.4)
Nodal stage
0 1 (1.3) 0 (
1 5 (6.7) 1 (1.3)
2 23 (30.7) 24 (30.8)
3 46 (61.3) 53 (56.7)
AJCC 7th stage
IIIA 9 (12.0) 10 (12.8)
IIIB 33 (44.0) 36 (46.2)
IIIC 33 (44.0) 32 (41.0)
AJCC 6th stage
II 4 (5.3) 6 (7.7)
IIIA 26 (34.7) 31 (39.7)
IIIB 18 (24.0) 20 (25.6)
IV 25 (33.3) 20 (25.6)
Duration from surgery to initiate chemotherapy, median (range, wk) 6.13 (2.7-8.7) 5.66 (2.5-7.8)
Values are presented as number (%) unless otherwise indicated. DS, docetaxel plus S-1; SP, S-1 plus cisplatin; ECOG, Eastern
Cooperative Oncology Group; WHO, World Health Organization; AJCC, American Joint Committee on Cancer.
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Treatment-related adverse event
DS (n=75) SP (n=78)
p-value
All G3/4 All G3/4  
Any 74 (98.7) 46 (61.3) 77 (98.7) 44 (56.4) 0.536
Hematologic toxicity
Febrile neutropenia 3 (4.0) 2 (2.7) 3 (3.8) 3 (3.8) 0.548
Neutropenia 51 (68.0) 32 (42.7) 28 (35.9) 30 (38.5) 0.351
Anemia 41 (54.0) 1 (1.3) 45 (57.6) 9 (11.5) 0.037
Thrombocytopenia 2 (2.6) 1 (1.3) 19 (24.3) 1 (1.3) < 0.001
Non-hematologic toxicity
Abdominal pain  24 (32.0) 3 (4.1) 15 (19.2) 2 (2.6) 0.193
Anorexia 48 (64.0) 5 (6.7) 47 (60.2) 5 (6.4) 0.892
Nausea 49 (65.3) 2 (2.7) 51 (65.4) 2 (2.6) 0.999
Vomiting 16 (21.3) 1 (1.3) 17 (21.8) 1 (1.3) 0.997
Hand foot syndrome 18 (24.0) 3 (4.1) 7 (9.0) 0 ( 0.025
Mucositis 39 (52.0) 8 (10.7) 18 (23.1) 2 (2.6) 0.001
Diarrhea 40 (53.3) 2 (2.7) 35 (44.9) 3 (3.8) 0.478
Paronychia 8 (10.7) 0 ( 0 ( 0 ( 0.003
Alopecia 34 (45.3) 0 ( 4 (5.1) 0 ( < 0.001
Fatigue 12 (16.0) 1 (1.3) 14 (18.0) 1 (1.3) 0.944
General weakness 16 (21.3) 1 (1.3) 23 (29.5) 2 (2.6) 0.493
Neuropathy 17 (22.7) 0 ( 15 (19.2) 1 (1.3) 0.487
Table 2. Adverse events (n=153)
Values are presented as number (%). One treatment related death in DS group: thromboembolism event. DS, docetaxel plus
S-1; SP, S-1 plus cisplatin.
Fig. 1.  Median relative dose intensities per regimen and cycle. Median relative dose intensities (RDIs) of S-1 in both groups
(A) and RDIs of docetaxel in docetaxel plus S-1 (DS) group or cisplatin in S-1 plus cisplatin (SP) group (B). 
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Results
1. Patient characteristics
Between November 2010 and July 2013, a total of 153 
patients from eight centers in South Korea were randomly
assigned to DS (n=75) or SP (n=78) treatment groups (S1 Fig.).
Patient demographics and baseline disease characteristics
were well balanced between the two groups. Poorly differ-
entiated and diffuse types of adenocarcinoma were the most
common histological type. Most of the patients had AJCC
seventh edition stage IIIB (n=69, 45.1%) or stage IIIC disease
(n=65, 42.5%) (Table 1). 
2. Treatment compliance and toxicity
The median number of treatment cycles in each group was
8 (range, 1 to 8 cycles). The median relative dose intensity
(RDI) was 0.86 for both docetaxel and S-1 in DS group and
0.83 for cisplatin and 0.86 for S-1 in SP group. The RDI of 
S-1 in both groups was reduced from the second cycle, and
the RDI of docetaxel in DS group and cisplatin in SP group
was reduced from the third cycle (Fig. 1). The number of the
patients who could not complete the full eight cycles of
chemotherapy was 24 (32.0%) in DS group and 26 (33.3%) in
SP group (p=0.683).
Most patients (98.7%) reported at least one adverse event.
The total incidence of grade 3 or 4 adverse events was 46
(61.3%) in DS group and 44 (56.4%) in SP group (p=0.536).
The most common grade 3 or 4 adverse event was neutrope-
nia (42.7% in DS group and 38.5% in SP group, p=0.351)
(Table 2). SP treatment was associated with more frequent
hematologic adverse events such as grade 3 or 4 anemia
(1.3% vs.11.5%, p=0.037) or any grade of thrombocytopenia
(2.6% vs. 24.3%, p < 0.001). However, grade 3 or 4 non-hema-
Cancer Res Treat. 2019;51(1):1-11
Delayed cycles Dose reduced cycles
DS (n=495) SP (n=512) DS (n=495) SP (n=512)
Hematologic 84 ( 152 ( 35 ( 33 (
Neutropenia 83 ( 149 ( 35 ( 31 (
Febrile neutropenia 1 ( 1 ( 0 ( 1 (
Anemia 0 ( 1 ( 0 ( 0 (
Thrombocytopenia 0 ( 1 ( 0 ( 1 (
Non-hematologic 46 ( 20 ( 36 ( 23 (
General weakness 8 ( 2 ( 4 ( 4 (
Nausea/Vomiting 5 ( 1 ( 5 ( 4 (
Patients' refusal 4 ( 6 ( 2 ( 0 (
Mucositis 4 ( 2 ( 9 ( 2 (
Urticaria/Skin rash 4 ( 0 ( 1 ( 0 (
Anorexia 3 ( 4 ( 3 ( 3 (
Hand-foot syndrome 3 ( 0 ( 4 ( 0 (
Weight loss 3 ( 0 ( 1 ( 3 (
Fatigue 0 ( 3 ( 3 ( 1 (
Diarrhea 0 ( 2 ( 1 ( 3 (
Hemorrhoid 2 ( 0 ( 0 ( 0 (
Nail Infection 2 ( 0 ( 1 ( 0 (
Abdominal pain 1 ( 0 ( 0 ( 2 (
Generalized edema 2 ( 0 ( 0 ( 0 (
Common cold 2 ( 0 ( 0 ( 0 (
Herpes zoster 1 ( 0 ( 1 ( 0 (
Intestinal obstruction 1 ( 0 ( 0 ( 0 (
Bilirubin elevation 1 ( 0 ( 1 ( 0 (
Dizziness 0 ( 0 ( 0 ( 1 (
Total, n (%) 130 (26.3) 172 (33.6) 71 (14.3) 56 (10.9)
Table 3. The reasons for chemotherapy cycle delays and reductions
DS, docetaxel plus S-1; SP, S-1 plus cisplatin.
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tologic adverse events including hand-foot syndrome (4.1%
vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001)
were more commonly observed in DS group. Grade 1 or 2
paronychia (10.7% vs. 0%, p=0.003) and alopecia (45.3% vs.
5.1%, p < 0.001) were also more common in DS group. There
was one treatment-related death in DS group, from a throm-
boembolic event. The day after starting the seventh cycle of
DS treatment, this 67-year-old female patient’s dyspnea on
exertion worsened, and the patient died due to left pul-
monary artery thromboembolism. The patient did not have
any other pre-disposing factor for pulmonary thromboem-
bolism.
Among total 495 treatment cycles for DS group and 512 
cycles for SP group, 130 cycles (26.3%) in DS group and 172
cycles (33.6%) in SP group (p=0.011) were delayed. The che-
motherapy dose was reduced in 71 cycles (14.3%) in DS
group and 56 cycles (10.9%) in SP group (p=0.104). Overall,
the most common reason for delay in the initiation of treat-
ment in each cycle and for the dose reduction was neutrope-
nia (76.8% for of delayed cycles and 52.0% of dose reduced
cycles) (Table 3). With respect to adverse events (Table 2),
treatment delays were more common in SP group which was
associated with more frequent hematologic toxicities,
whether dose reductions were more common in DS group
which experienced more non-hematologic toxicities.
The treatment discontinuations were permanently devel-
oped from 24 patients in DS group and from 26 patients in
SP groups. The main reason for discontinued treatment was
toxicity (12 [50.0%] in DS group and 13 [50.0%] in SP group)
(S1 Fig.). The reasons for discontinuation due to toxicity in
DS group were allergic reaction (n=3), neutropenia, afferent
loop syndrome, skin rash, thromboembolic event, ileus,
hand-foot syndrome, general weakness, dyspnea, and nau-
sea/vomiting (n=1 for each). In SP group, toxicities that 
resulted in treatment discontinuation were neutropenia
(n=3), general weakness (n=2), thrombocytopenia, myocar-
diac infarction, neuropathy, skin rash, anorexia, acute cere-
bral infarction and pneumonitis (n=1 for each). Three pati-
ents in DS group and four patients in SP group were off the
study because of gastric cancer recurrence during the course
of the trial treatment. 
3. Survival analysis
The median duration of follow-up was 53.6 months (range,
1.1 to 74.0 months) for DS group and 57.3 months (range, 1.7
to 73.1 months) for SP group. At the cut-off date for data col-
lection on April 30, 2017, 43 patients (57.3%) in DS group and
40 patients (53.3%) in SP group developed DFS events. The
most common site of recurrence was the peritoneum (20 and
11 cases in DS and SP groups, respectively) (Table comparing
pattern of recurrences in S2 Table). Primary endpoint, the 
3-year DFS rate, was 49.1% in DS group (median DFS, 35.5
months) and 52.5% in SP group (median DFS, 39.3 months).
The 3-year survival rate was 60.7% among DS group and
66.4% among SP group, with 31 (41.3%) and 32 (41.0%)
deaths in DS group (median OS, not reached) and SP group
(median OS, 64.4 months), during the follow-up period.
Every death was cancer-related. There was no statistically
significant difference in DFS (HR, 1.201; 95% confidence 
Choong-kun Lee, Phase III Adjuvant S-1 Based Doublet for GC
Fig. 2.  Kaplan-Meier curves of disease-free survival (A) and overall survival (B) in the intention-to-treat population. 
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interval [CI], 0.781 to 1.848; p=0.404) or OS (HR, 1.081; 95%
CI, 0.659 to 1.772; p=0.757) between DS and SP groups 
(Fig. 2). The DFS and OS of eligible patients were also ana-
lyzed according to sex, age, ECOG performance status, can-
cer stage based on AJCC seventh, tumor stage, and nodal
stage. Stage IIIC subgroup among SP group showed signifi-
cant benefit of DFS (HR, 2.018; 95% CI, 1.108 to 3.675;
p=0.022), and OS (HR, 2.149; 95% CI, 1.018 to 4.533; p=0.048),
but there was no significant interaction between the treat-
ment group and any other subgroups in terms of survival
(Forest plots in S3 Fig.).   
Discussion
This POST trial is the first randomized phase III trial com-
paring efficacy and tolerability of two S-1 based doublet reg-
imens, DS and SP, in curatively resected stage III gastric
cancer patients based on the AJCC seventh edition. Unfortu-
nately, because of the early termination, we could not show
any statistically significant advantage in terms of OS or DFS
for either regimen. However, both treatments seem to be an
effective and tolerable option for these patients.
S-1 was regarded to have advantages over capecitabine
among Asians in terms of reducing incidence of toxicities
such as stomatitis and hand-foot syndrome [15]. Several
chemotherapeutic regimens combining S-1 with other anti-
cancer agents have been shown to improve the response rate
or median survival time in gastric cancer, mostly in phase II
studies [16-20]. From among many possible combinations of
anti-cancer drugs, we compared S-1 plus taxane (DS) with 
S-1 plus platinum (SP) in this phase III study. Taxanes like
docetaxel has been shown to prolong survival when used as
a palliative treatment for advanced gastric cancer [21]. The
phase III START trial showed that the combination of S-1 and
docetaxel is more effective than S-1 monotherapy for
metastatic gastric cancer patients, with longer survival (12.5
months vs. 10.8 months, p=0.032) and a significant (16%) 
reduction in the risk of death [22]. In addition, a phase II
study comparing docetaxel plus S-1 to docetaxel plus cis-
platin suggested that DS was more effective (OS, 16 vs. 8.3
months) among chemotherapy naïve stage IV advanced gas-
tric cancer patients [9]. Recently, another large phase III 
adjuvant trial (SAMIT) result was published [14]. The study
tried to assess the superiority of adding paclitaxel to oral flu-
oropyrimidines as sequential treatment to locally advanced
gastric cancer patients after D2 dissection, but the trial failed
to show survival improvement. Cisplatin is generally accep-
ted as a benchmark treatment when combined with 5-fluo-
rouracil for advanced gastric cancer, although it has several
drawbacks, including high incidences of nausea, vomiting
[23] and renal toxicity [24]. Cisplatin has also been shown to
have an additive effect when combined with S-1 in advanced
gastric cancer. In the phase III SPIRIT trial, SP resulted in sig-
nificantly longer survival compared to S-1 alone (OS, 13
months vs. 11 months; p=0.04) and a better response rate
(54% vs. 31%) [25]. Based on these previous studies, the aim
of this study was compare two S-1 based doublets to deter-
mine whether there was a significant increase in the 3-year
DFS rate when DS or SP were used to treat patients with
stage III gastric cancer.
The addition of docetaxel or cisplatin to S-1 was well-tol-
erated. We compared compliances and toxicities of our study
(POST) with three published phase III studies of adjuvant
chemotherapy for gastric cancer; ACTS-GC, CLASSIC, and
SAMIT (Table 4) [5,6,14]. Sixty-eight percent of patients in
DS group and 66.7% of patients in SP group completed 8 
cycles as planned, which was comparable to that achieved in
the ACTS-GC (65.8% for S-1 monotherapy), SAMIT (61.5%
for S-1 monotherapy or 70.4% for paclitaxel then S-1 sequen-
tial therapy), and CLASSIC (67% for capecitabine plus oxali-
platin) trials. The median RDI was 86% for S-1 in both
groups, 86% for docetaxel in DS group, and 83% for cisplatin
in SP group. These findings were also comparable to those
of CLASSIC trial (capecitabine 85% and oxaliplatin 98%).
Comparing toxicities among patients treated using DS or SP
with those who were administered S-1 monotherapy (ACTS-
GC and SAMIT) revealed that adding docetaxel or cisplatin
increased hematologic toxicity (neutropenia and anemia) but
did not increased non-hematologic toxicities. In the capeci-
tabine plus oxaliplatin group of the CLASSIC trial, 56% of
patients experienced grade 3 or 4 adverse events, while in
our study 61.3% and 56.4% of patients in DS and SP groups,
respectively. A comparison of the treatment groups in this
study revealed that patients treated with DS more frequently
had non-hematologic toxicities, while those treated with SP
more frequently suffered from hematologic toxicities (Table 2).
These higher incidences of non-hematologic adverse events
in DS group was related to more frequent dose reduction,
and higher incidences of hematologic adverse events 
observed in SP group was related to more frequent treatment
cycle delays (Table 3). S4 Table shows a comparison of com-
pliancy rates and toxicities in previously reported adjuvant
DS or SP chemotherapy trials, excluding those in which S-1
was given as a monotherapy during the first cycle [26-30].
The relative small number of accrued patients reduced the
statistical power of our study. It is hard to compare survival
outcomes of our study to that of previous studies, because
this study only included stage III gastric cancer patients 
diagnosed on the basis of the AJCC seventh edition, and the
previous adjuvant phase III studies included patients with
stage II or III gastric cancer based on the AJCC sixth edition
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[6,8]. The more recent staging system classifies more than 15
positive nodes (N3b) as stage IIB or III, whereas it would
have been classified as stage IV by the AJCC sixth edition
staging system. Furthermore, invasion of the adjacent struc-
ture (T4b in the AJCC seventh edition and T4 in the AJCC
sixth edition) with any positive node was classed as stage IV
disease in the AJCC sixth edition but stage IIIB or IIIC disease
in the AJCC seventh edition (S5 Fig.). Comparing the distri-
bution of disease stages according to the AJCC seventh and
sixth editions showed that 45 patients (3 patients with stage
IIIA, 15 patients with stage IIIB, and 27 patients with stage
IIIC; 29.4% in total) in this study would have been stage IV 
according to the AJCC sixth edition, and would thus not be
eligible for the previous ACTS-GC or CLASSIC trials (S6
Fig.). So it is difficult to compare precisely, but our study has
enrolled higher stage patients, and survival is similar when
compared to Stage IIIB patients of CLASSIC or ACTS-GC tri-
als. 
In conclusion, postoperative DS and SP regimens were
well tolerated, and the safety data presented here are com-
parable with that of previous studies. Since the trial was
closed early, it didn’t have sufficient statistical power to
show a survival advantage for either regimen. We believe
that our preliminary findings warrant further clinical inves-
tigation.
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